Shenogen’s Charlie Wang elected as member of

The Recruitment Program of Global Experts

 

Oct 20th, 2015 Beijing China

 

Shenogen’s Charlie Wang was elected as a member of the Recruitment Program of Global Experts.

Dr. Charlie Wang is a co-founder, Chief Science Officer & Member of Board of Directors of Shenogen Pharma Group. He received Ph.D. degree from Washington University at St. Louis. He completed postdoctoral training in Princeton University, and was Assistant Professor of Harvard Medical School. Dr. Wang was a professor of pathology in Creighton University, director of an oncology laboratory when he founded Shenogen together with Dr. Kun Meng. Dr. Wang has over 20-year experience in cancer research. He is expert in molecular cancer biology, especially cell proliferation, differentiation and apoptosis. Dr. Wang is dedicated to study breast cancer related genes. He identified and cloned a novel membrane estrogen receptor ER-alpha 36 and studied its functions. His findings greatly contributed to the understanding of the pathogenesis of breast cancer, and got high remarks from Elwood Jensen, fellow of National Academy of Sciences and V. Craig Jordan, “Father of Tamoxifen”. Dr. Wang received grants from NIH, American Cancer Society, the US Department of Defense and Susan G. Komen Foundation. Dr. Wang has authored/ co-authored more than 70 peer-reviewed papers, host and attended many key scientific conferences, written four books and owned three granted patents. Dr. Wang returned China in 2014. He was elected into the Recruitment Program of Global Experts, Beijing Haiju Program and Shandong Taishan Academician Program.

 

 

About Shenogen

Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently completing Ph II clinical trial for treatment of advanced hepatocellular carcinoma.

(For more information, please visit www.shenogen.com.cn.)

 

 

2015年10月20日

Shenogen’s Charlie Wang elected as member of

添加时间: